GCM
AMED

Gladius Capital Management’s Amedisys AMED Stock Holding History

Gladius Capital Management’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-607
Closed -$99K – 269
2021
Q4 		$99K Buy
+607
New +$97.5K 0.01% 250

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Gladius Capital Management's AMED Position: Q1 2022 in Review

Gladius Capital Management sold out of Amedisys (AMED) in Q1 2022, closing a stake of 607 shares — an estimated $99K sold.

Gladius Capital Management first reported a position in AMED in Q4 2021 and held it in 1 quarter. The position peaked at $99K in Q4 2021. 328 funds tracked by Wall St. Rank hold AMED as of Q1 2022.

  • Gladius Capital Management reported no remaining Amedisys position as of Q1 2022 after selling out during the quarter.
  • Gladius Capital Management sold 607 Amedisys shares in Q1 2022, an estimated $99K.
  • Gladius Capital Management first reported a position in Amedisys in Q4 2021 and held it in 1 quarter.
  • Gladius Capital Management's Amedisys position peaked at $99K in Q4 2021.
  • 328 funds tracked by Wall St. Rank held Amedisys as of Q1 2022.

Based on Gladius Capital Management's 13F filing for Q1 2022, filed 29 Apr 2022.